NM
CYT

Newtyn Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Newtyn Management’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,021,500
Closed -$9.19M – 49
2023
Q4 		$9.19M Buy
3,021,500
+521,056
+21% +$1.58M 1.8% 18
2023
Q3 		$7.1M Buy
2,500,444
+1,142,395
+84% +$3.15M 1.75% 16
2023
Q2 		$3.53M Buy
1,358,049
+405,102
+43% +$848K 0.83% 27
2023
Q1 		$1.73M Sell
952,947
-67,053
-7% -$109K 0.34% 51
2022
Q4 		$1.68M Buy
1,020,000
+365,888
+56% +$587K 0.35% 40
2022
Q3 		$1.26M Buy
654,112
+47,864
+8% +$125K 0.28% 47
2022
Q2 		$1.81M Buy
+606,248
New +$1.55M 0.34% 45

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Newtyn Management's CYT Position: Q1 2024 in Review

Newtyn Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 3,021,500 shares — an estimated $9.19M sold.

Newtyn Management first reported a position in CYT in Q2 2022 and held it in 7 quarters. The position peaked at $9.19M in Q4 2023. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Newtyn Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Newtyn Management sold 3,021,500 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $9.19M.
  • Newtyn Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
  • Newtyn Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $9.19M in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Newtyn Management's 13F filing for Q1 2024, filed 15 May 2024.